Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 19Neoplasms 11Polycystic Ovary Syndrome 9Neoplasm Metastasis 4Multiple Myeloma 4Melanoma 4Vomiting 3Prostatic Neoplasms 3Leukemia, Myeloid, Acute 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Triple Negative Breast Neoplasms 2Solid Tumors 2Skin Neoplasms 2Sarcoma 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Peripheral Nervous System Diseases 2Ovarian Neoplasms 2Obesity 2Nausea 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, B-Cell 2Leukemia 2Insulin Resistance 2Inflammation 2Diabetes Mellitus 2Colorectal Neoplasms 2Cognitive Dysfunction 2

Interventions

Misoprostol 5Uterine Myomectomy 3Saline Solution 3relugolix 2dienogest 2carbetocin 2Uterine Artery Embolization 2Tranexamic Acid 2Tourniquets 2Lidocaine 2Leuprolide 2Ascorbic Acid 2ulipristal 1telapristone acetate 1ramosetron 1pirfenidone 1estradiol, norethindrone drug combination 1Vasopressins 1Triptorelin Pamoate 1Tablets 1Sodium Chloride 1Sevoflurane 1Respiration, Artificial 1Remifentanil 1Propofol 1Population Groups 1Oxytocin 1Nuclear Receptor Subfamily 4, Group A, Member 2 1Morcellation 1Methylergonovine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Myofibroma × Tablets × Clear all
NCT03156127 2017-08-10

A Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet

Boryung Pharmaceutical Co., Ltd

Phase 1 Withdrawn

Myofibroma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡